Metformin Hydrochloride Extended-Release Tablets, USP 500 mg, a) 50 count (NDC 50268-531-15); b) 90 count (NDC 42291-610-90); c) 180 count (NDC 42291-610-18); d) 360 count (NDC 42291-610-36); e) 1000 count (NDC 42291-610-10) bottles, Rx Only, Manufactured

FDA recall notice · announced June 24, 2020 · Avkare

Class II FDA/FSIS Class II: use may cause temporary or medically reversible adverse health consequences.

The product

Metformin Hydrochloride Extended-Release Tablets, USP 500 mg, a) 50 count (NDC 50268-531-15); b) 90 count (NDC 42291-610-90); c) 180 count (NDC 42291-610-18); d) 360 count (NDC 42291-610-36); e) 1000 count (NDC 42291-610-10) bottles, Rx Only, Manufactured for: AvKARE, Inc. Pulaski, TN 38478

Reason for recall

CGMP Deviations: FDA analysis detected N-Nitrosodimethylamine (NDMA) impurity above the acceptable intake level

Notes

Distribution: Nationwide.
Lot/code information: Lots: a) 23537 Exp. 06/30/2020, 23613 Exp. 06/30/2020, 24083 Exp. 06/30/2020, 24291 Exp. 06/30/2020, 24725 Exp. 06/30/2020, 25637 Exp. 06/30/2021, 25751 Exp. 07/31/2021; b) 22073 Exp. 06/30/2020, 22460 Exp. 07/31/2020, 22539 Exp. 09/30/2020, 22540 Exp. 09/30/2020, 23299 Exp. 01/31/2021, 23300 Exp. 01/31/2021, 23484 Exp. 01/31/2021, 23917 Exp. 03/31/2021, 24477 Exp. 06/30/2021, 24514 Exp. 06/30/2021, 24945 Exp. 08/31/2021, 25591 Exp. 10/31/2021, 25590 Exp. 10/31/2021, 26004 Exp. 11/30/2021, 26322 Exp. 01/31/2021, 26339 Exp. 02/28/2022, 26520 Exp. 01/31/2022, 26588 Exp. 02/28/2022; c) 22202 Exp. 06/30/2020, 22541 Exp. 09/30/2020, 23293 Exp. 01/31/2021, 23475 Exp. 01/31/2021, 23658 Exp. 03/31/2021, 23979 Exp. 03/31/2021, 24303 Exp. 06/30/2021, 24476 Exp. 06/30/2021, 24550 Exp. 06/30/2021, 24804 Exp. 07/31/2021, 25380 Exp. 08/31/2021, 25592 Exp. 10/31/2021, 25736 Exp. 10/31/2021, 26005 Exp. 11/30/2021, 26006 Exp. 10/31/2021, 26326 Exp. 01/31/2022, 26483 Exp. 02/28/2022, 26484 Exp. 02/28/2022,26589 Exp. 02/28/2022; d) 22430 Exp. 06/30/2020, 22538 Exp. 09/30/2020, 22638 Exp. 09/30/2020, 22639 Exp. 09/30/2020, 23292 Exp. 01/31/2021, 23291 Exp. 01/31/2021, 23344 Exp. 01/31/2021, 23631 Exp. 01/31/2021, 23707 Exp. 03/31/2021, 23706 Exp. 03/31/2021, 24164 Exp. 05/31/2021, 24165 Exp. 05/31/2021, 24340 Exp. 06/30/2021, 24474 Exp. 06/30/2021, 24475 Exp. 06/30/2021, 24548 Exp. 06/30/2021, 24738 Exp. 07/31/2021, 24739 Exp. 07/31/2021, 24905 Exp. 07/31/2021, 24906 Exp. 08/31/2021, 25379 Exp. 08/31/2021, 25378 Exp. 08/31/2021, 25627 Exp. 10/31/2021, 25664 Exp. 10/31/2021, 26131 Exp. 01/31/2022, 26340 Exp. 01/31/2022, 26341 Exp. 02/28/2022, 26590 Exp. 02/28/2022, 26591 Exp. 02/28/2022; e) HH01618A Exp. 07/31/2020, HH01718A Exp. 07/31/2020, HH01818A Exp. 07/31/2020, HH01918A Exp. 07/31/2020, HH02018A Exp. 08/31/2020, HH05018A Exp. 08/31/2020, HH05118A Exp. 08/31/2020, HH05218A Exp. 08/31/2020, HH05318A Exp. 08/31/2020, HH05418A Exp. 08/31/2020, HH05518A Exp. 08/31/2020, HH05618A Exp. 0
Quantity: 1,586,913 bottles
Status: Terminated
Products in this recall event:
- Metformin Hydrochloride Extended-Release Tablets, USP 750 mg a) 90 count (NDC 42291-611-90) b) 180 count (NDC 42291-611-18) c) 500 count (NDC 42291-611-50) bottles, Rx Only Manufactured for: AvKARE, I (D-1304-2020)
- Metformin Hydrochloride Extended-Release Tablets, USP 500 mg, a) 50 count (NDC 50268-531-15); b) 90 count (NDC 42291-610-90); c) 180 count (NDC 42291-610-18); d) 360 count (NDC 42291-610-36); e) 1000 (D-1305-2020)

Source: U.S. Food and Drug Administration public recall data. This page reports official records and is not legal, medical, or repair advice.